MENU
+Compare
ALLK
Stock ticker: NASDAQ
AS OF
May 9 closing price
Price
$0.33
Change
-$0.00 (-0.00%)
Capitalization
29.63M

ALLK Allakos Forecast, Technical & Fundamental Analysis

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases... Show more

ALLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALLK with price predictions
May 09, 2025

ALLK in upward trend: 10-day moving average crossed above 50-day moving average on April 08, 2025

The 10-day moving average for ALLK crossed bullishly above the 50-day moving average on April 08, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 02, 2025. You may want to consider a long position or call options on ALLK as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ALLK moved above its 50-day moving average on April 02, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLK advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 148 cases where ALLK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for ALLK turned negative on May 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALLK broke above its upper Bollinger Band on May 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (14.691). P/E Ratio (0.000) is within average values for comparable stocks, (62.716). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.861). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (253.146).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ALLK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ALLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLK is expected to report earnings to fall ∞% to -28 cents per share on May 09

Allakos ALLK Stock Earnings Reports
Q1'25
Est.
$-0.29
Q4'24
Beat
by $0.19
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.03
Q1'24
Missed
by $0.37
The last earnings report on March 12 showed earnings per share of 0 cents, beating the estimate of -18 cents. With 153.57K shares outstanding, the current market capitalization sits at 29.63M.
A.I. Advisor
published General Information

General Information

a provider of antibody therapeutics for allergic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
825 Industrial Road
Phone
+1 650 597-5002
Employees
131
Web
https://www.allakos.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NEWT10.380.16
+1.57%
NewtekOne
INVA18.56-0.02
-0.11%
Innoviva
OTIS97.00-0.32
-0.33%
Otis Worldwide Corp
FIZZ43.54-0.26
-0.59%
National Beverage Corp
USEG1.13-0.01
-0.88%
US Energy Corp

ALLK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLK has been loosely correlated with VERU. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLK jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
+0.18%
VERU - ALLK
51%
Loosely correlated
-3.56%
AXON - ALLK
38%
Loosely correlated
-0.33%
IMCR - ALLK
33%
Loosely correlated
-4.67%
AMRN - ALLK
32%
Poorly correlated
-2.80%
GANX - ALLK
31%
Poorly correlated
-4.20%
More